Sheets Smith Wealth Management Buys 1,670 Shares of Thermo Fisher Scientific Inc. $TMO

Sheets Smith Wealth Management lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 47.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,200 shares of the medical research company’s stock after acquiring an additional 1,670 shares during the quarter. Sheets Smith Wealth Management’s holdings in Thermo Fisher Scientific were worth $2,607,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Bank OZK purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at about $1,096,000. Ausdal Financial Partners Inc. bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $456,000. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $7,505,000. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter valued at $15,501,867,000. Finally, German American Bancorp Inc. bought a new position in Thermo Fisher Scientific during the second quarter valued at $4,920,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.4%

Shares of NYSE TMO opened at $621.87 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $647.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company has a market cap of $229.94 billion, a price-to-earnings ratio of 33.45, a PEG ratio of 2.53 and a beta of 0.85. The business’s 50 day moving average price is $558.64 and its 200-day moving average price is $512.08.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada boosted their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a report on Friday, July 24th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their target price for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.